According to GlaxoSmithKline's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.32053. At the end of 2023 the company had a P/S ratio of 2.01.
Year | P/S ratio | Change |
---|---|---|
2023 | 2.01 | -0.47% |
2022 | 2.02 | -25.72% |
2021 | 2.73 | 29.68% |
2020 | 2.10 | -22.19% |
2019 | 2.70 | 17.15% |
2018 | 2.31 | 3.51% |
2017 | 2.23 | -12.8% |
2016 | 2.55 | -6.69% |
2015 | 2.74 | -1.16% |
2014 | 2.77 | -10.25% |
2013 | 3.09 | 23.35% |
2012 | 2.50 | -5.99% |
2011 | 2.66 | 13.69% |
2010 | 2.34 | -4.53% |
2009 | 2.45 | 10.57% |
2008 | 2.22 | -27.13% |
2007 | 3.04 | -13.49% |
2006 | 3.52 | -7.66% |
2005 | 3.81 | 1.99% |
2004 | 3.73 | -1.39% |
2003 | 3.79 | -10.03% |
2002 | 4.21 | -28.97% |
2001 | 5.93 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Novartis NVS | 3.86 | 66.42% | ๐จ๐ญ Switzerland |
Pfizer PFE | 2.69 | 15.88% | ๐บ๐ธ USA |
Sanofi SNY | 2.46 | 5.83% | ๐ซ๐ท France |
Merck MRK | 5.55 | 139.20% | ๐บ๐ธ USA |
AstraZeneca AZN | 4.62 | 99.08% | ๐ฌ๐ง UK |
Teva Pharmaceutical Industries TEVA | 1.02 | -56.01% | ๐ฎ๐ฑ Israel |
Dynavax Technologies
DVAX | 6.98 | 200.72% | ๐บ๐ธ USA |